![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | SGO2 | Human | (-)-alpha-phellandrene | increases expression | EXP | | 6480464 | alpha phellandrene results in increased expression of SGO2A mRNA | CTD | PMID:25075043 | SGO2 | Human | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SGO2 mRNA | CTD | PMID:22079256 | SGO2 | Human | 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane | decreases expression | EXP | | 6480464 | o and p'-DDT results in decreased expression of SGO2 mRNA | CTD | PMID:18204070 | SGO2 | Human | 1,1-dichloroethene | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | vinylidene chloride results in increased expression of SGO2A mRNA | CTD | PMID:26682919 | SGO2 | Human | 1-naphthyl isothiocyanate | increases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | 1-Naphthylisothiocyanate results in increased expression of SGO2 mRNA | CTD | PMID:30723492 | SGO2 | Human | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of SGO2 mRNA | CTD | PMID:19167446 | SGO2 | Human | 17beta-estradiol | multiple interactions | ISO | Sgo2 (Rattus norvegicus) | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SGO2 mRNA | CTD | PMID:32741896 | SGO2 | Human | 17beta-estradiol 3-benzoate | multiple interactions | ISO | Sgo2 (Rattus norvegicus) | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SGO2 mRNA | CTD | PMID:32741896 | SGO2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of SGO2 mRNA | CTD | PMID:22574217 | SGO2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SGO2 mRNA | CTD | PMID:32109520 more ... | SGO2 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Sgo2a (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of SGO2A mRNA | CTD | PMID:26377647 | SGO2 | Human | 2,4-dibromophenyl 2,4,5-tribromophenyl ether | affects expression | ISO | Sgo2a (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:38648751 | SGO2 | Human | 2-methylcholine | affects expression | EXP | | 6480464 | beta-methylcholine affects the expression of SGO2 mRNA | CTD | PMID:21179406 | SGO2 | Human | 3-chloropropane-1,2-diol | increases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | alpha-Chlorohydrin results in increased expression of SGO2 mRNA | CTD | PMID:38301995 | SGO2 | Human | 4,4'-sulfonyldiphenol | increases expression | EXP | | 6480464 | bisphenol S results in increased expression of SGO2 mRNA | CTD | PMID:27685785 | SGO2 | Human | 4-hydroxynon-2-enal | decreases expression | ISO | Sgo2a (Mus musculus) | 6480464 | 4-hydroxy-2-nonenal results in decreased expression of SGO2 mRNA | CTD | PMID:19191707 | SGO2 | Human | acetamide | increases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | acetamide results in increased expression of SGO2 mRNA | CTD | PMID:31881176 | SGO2 | Human | acrylamide | decreases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Acrylamide results in decreased expression of SGO2 mRNA | CTD | PMID:28606764 | SGO2 | Human | aflatoxin B1 | affects expression | EXP | | 6480464 | Aflatoxin B1 affects the expression of SGO2 protein | CTD | PMID:20106945 | SGO2 | Human | aflatoxin B1 | decreases methylation | EXP | | 6480464 | Aflatoxin B1 results in decreased methylation of SGO2 gene | CTD | PMID:27153756 | SGO2 | Human | all-trans-retinoic acid | decreases expression | EXP | | 6480464 | Tretinoin results in decreased expression of SGO2 mRNA | CTD | PMID:33167477 | SGO2 | Human | alpha-phellandrene | increases expression | EXP | | 6480464 | alpha phellandrene results in increased expression of SGO2A mRNA | CTD | PMID:25075043 | SGO2 | Human | androstane-3,17-dione | increases expression | EXP | | 6480464 | androstane-3 and 17-dione results in increased expression of SGO2 mRNA | CTD | PMID:38122923 | SGO2 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of SGO2 mRNA | CTD | PMID:33212167 | SGO2 | Human | arsane | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of SGO2 gene | CTD | PMID:25304211 | SGO2 | Human | arsenic atom | affects methylation | EXP | | 6480464 | Arsenic affects the methylation of SGO2 gene | CTD | PMID:25304211 | SGO2 | Human | azathioprine | decreases expression | EXP | | 6480464 | Azathioprine results in decreased expression of SGO2 mRNA | CTD | PMID:22623647 | SGO2 | Human | benzo[a]pyrene | decreases expression | EXP | | 6480464 | Benzo(a)pyrene results in decreased expression of SGO2 mRNA | CTD | PMID:21632981 | SGO2 | Human | benzo[a]pyrene | affects methylation | EXP | | 6480464 | Benzo(a)pyrene affects the methylation of SGO2 promoter | CTD | PMID:27901495 | SGO2 | Human | benzo[a]pyrene | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | Benzo(a)pyrene metabolite results in increased expression of SGO2A mRNA | CTD | PMID:32553695 | SGO2 | Human | benzo[a]pyrene diol epoxide I | decreases expression | EXP | | 6480464 | 7 more ... | CTD | PMID:19150397 and PMID:20382639 | SGO2 | Human | beta-lapachone | decreases expression | EXP | | 6480464 | beta-lapachone results in decreased expression of SGO2 mRNA | CTD | PMID:38218311 | SGO2 | Human | bis(2-ethylhexyl) phthalate | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | Diethylhexyl Phthalate results in increased expression of SGO2A mRNA | CTD | PMID:34319233 | SGO2 | Human | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of SGO2 mRNA | CTD | PMID:19490990 and PMID:29275510 | SGO2 | Human | bisphenol A | increases methylation | ISO | Sgo2 (Rattus norvegicus) | 6480464 | bisphenol A results in increased methylation of SGO2 gene | CTD | PMID:28505145 | SGO2 | Human | bisphenol A | decreases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | bisphenol A results in decreased expression of SGO2 mRNA | CTD | PMID:25181051 more ... | SGO2 | Human | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of SGO2 protein | CTD | PMID:23142537 | SGO2 | Human | buta-1,3-diene | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | 1 and 3-butadiene results in increased expression of SGO2A mRNA | CTD | PMID:29038090 | SGO2 | Human | cadmium dichloride | decreases expression | ISO | Sgo2a (Mus musculus) | 6480464 | Cadmium Chloride results in decreased expression of SGO2 mRNA | CTD | PMID:24982889 | SGO2 | Human | caffeine | decreases phosphorylation | EXP | | 6480464 | Caffeine results in decreased phosphorylation of SGO2 protein | CTD | PMID:35688186 | SGO2 | Human | calcitriol | decreases expression | EXP | | 6480464 | Calcitriol results in decreased expression of SGO2 mRNA | CTD | PMID:21592394 | SGO2 | Human | calcitriol | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of SGO2 mRNA | CTD | PMID:21592394 | SGO2 | Human | carbon nanotube | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | SGO2 | Human | cisplatin | decreases expression | EXP | | 6480464 | Cisplatin results in decreased expression of SGO2 mRNA | CTD | PMID:27594783 | SGO2 | Human | copper atom | increases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Copper results in increased expression of SGO2 mRNA | CTD | PMID:30556269 | SGO2 | Human | copper(0) | increases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Copper results in increased expression of SGO2 mRNA | CTD | PMID:30556269 | SGO2 | Human | copper(II) sulfate | decreases expression | EXP | | 6480464 | Copper Sulfate results in decreased expression of SGO2 mRNA | CTD | PMID:19549813 | SGO2 | Human | coumestrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with 2 more ... | CTD | PMID:19167446 | SGO2 | Human | coumestrol | increases expression | EXP | | 6480464 | Coumestrol results in increased expression of SGO2 mRNA | CTD | PMID:19167446 | SGO2 | Human | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of SGO2 mRNA | CTD | PMID:20106945 more ... | SGO2 | Human | deguelin | increases expression | EXP | | 6480464 | deguelin results in increased expression of SGO2 mRNA | CTD | PMID:33512557 | SGO2 | Human | diallyl trisulfide | decreases expression | EXP | | 6480464 | diallyl trisulfide results in decreased expression of SGO2 mRNA | CTD | PMID:34995734 | SGO2 | Human | dichloroacetic acid | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | Dichloroacetic Acid results in increased expression of SGO2A mRNA | CTD | PMID:28962523 | SGO2 | Human | dicrotophos | decreases expression | EXP | | 6480464 | dicrotophos results in decreased expression of SGO2 mRNA | CTD | PMID:28302478 | SGO2 | Human | diethylstilbestrol | increases expression | EXP | | 6480464 | Diethylstilbestrol results in increased expression of SGO2 mRNA | CTD | PMID:36621641 | SGO2 | Human | dimethylarsinic acid | increases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Cacodylic Acid results in increased expression of SGO2 mRNA | CTD | PMID:37567419 | SGO2 | Human | doxorubicin | decreases expression | EXP | | 6480464 | Doxorubicin results in decreased expression of SGO2 mRNA | CTD | PMID:29803840 | SGO2 | Human | Enterolactone | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with 2 and 3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SGO2 mRNA | CTD | PMID:19167446 | SGO2 | Human | folic acid | multiple interactions | EXP | | 6480464 | [Folic Acid deficiency co-treated with Methotrexate] results in decreased expression of SGO2 mRNA | CTD | PMID:24657277 | SGO2 | Human | formaldehyde | decreases expression | EXP | | 6480464 | Formaldehyde results in decreased expression of SGO2 mRNA | CTD | PMID:23649840 | SGO2 | Human | FR900359 | decreases phosphorylation | EXP | | 6480464 | FR900359 results in decreased phosphorylation of SGO2 protein | CTD | PMID:37730182 | SGO2 | Human | fragrance | increases expression | EXP | | 6480464 | Perfume results in increased expression of SGO2 mRNA | CTD | PMID:24768652 | SGO2 | Human | furan | decreases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | furan results in decreased expression of SGO2 mRNA | CTD | PMID:25539665 | SGO2 | Human | gentamycin | decreases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Gentamicins results in decreased expression of SGO2 mRNA | CTD | PMID:33387578 | SGO2 | Human | hydrogen peroxide | affects expression | EXP | | 6480464 | Hydrogen Peroxide affects the expression of SGO2 mRNA | CTD | PMID:20044591 | SGO2 | Human | irinotecan | decreases expression | EXP | | 6480464 | Irinotecan analog results in decreased expression of SGO2 mRNA | CTD | PMID:18927307 | SGO2 | Human | leflunomide | decreases expression | EXP | | 6480464 | leflunomide results in decreased expression of SGO2 mRNA | CTD | PMID:28988120 | SGO2 | Human | lidocaine | increases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Lidocaine results in increased expression of SGO2 mRNA | CTD | PMID:35283115 | SGO2 | Human | lucanthone | decreases expression | EXP | | 6480464 | Lucanthone results in decreased expression of SGO2 mRNA | CTD | PMID:21148553 | SGO2 | Human | methotrexate | multiple interactions | EXP | | 6480464 | [Folic Acid deficiency co-treated with Methotrexate] results in decreased expression of SGO2 mRNA | CTD | PMID:24657277 | SGO2 | Human | methotrexate | decreases expression | EXP | | 6480464 | Methotrexate results in decreased expression of SGO2 mRNA | CTD | PMID:24657277 | SGO2 | Human | methylparaben | decreases expression | EXP | | 6480464 | methylparaben results in decreased expression of SGO2 mRNA | CTD | PMID:31745603 | SGO2 | Human | N-methyl-4-phenylpyridinium | decreases expression | EXP | | 6480464 | 1-Methyl-4-phenylpyridinium results in decreased expression of SGO2 mRNA | CTD | PMID:24810058 | SGO2 | Human | N-Nitrosopyrrolidine | decreases expression | EXP | | 6480464 | N-Nitrosopyrrolidine results in decreased expression of SGO2 mRNA | CTD | PMID:32234424 | SGO2 | Human | ochratoxin A | increases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | ochratoxin A results in increased expression of SGO2 mRNA | CTD | PMID:38301995 | SGO2 | Human | ozone | multiple interactions | ISO | Sgo2a (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of SGO2A mRNA more ... | CTD | PMID:25658374 and PMID:34911549 | SGO2 | Human | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of SGO2 mRNA | CTD | PMID:22230336 | SGO2 | Human | paracetamol | decreases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Acetaminophen results in decreased expression of SGO2 mRNA | CTD | PMID:33387578 | SGO2 | Human | phenobarbital | multiple interactions | ISO | Sgo2a (Mus musculus) | 6480464 | NR1I3 protein affects the reaction [Phenobarbital results in increased expression of SGO2 mRNA] | CTD | PMID:19482888 | SGO2 | Human | phenobarbital | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | Phenobarbital results in increased expression of SGO2 mRNA | CTD | PMID:19482888 and PMID:23091169 | SGO2 | Human | picoxystrobin | increases expression | EXP | | 6480464 | picoxystrobin results in increased expression of SGO2 mRNA | CTD | PMID:33512557 | SGO2 | Human | pirinixic acid | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | pirinixic acid results in increased expression of SGO2 mRNA | CTD | PMID:20813756 | SGO2 | Human | pirinixic acid | multiple interactions | EXP | | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of SGO2 mRNA | CTD | PMID:19710929 | SGO2 | Human | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SGO2 mRNA | CTD | PMID:22079256 | SGO2 | Human | potassium chromate | decreases expression | EXP | | 6480464 | potassium chromate(VI) results in decreased expression of SGO2 mRNA | CTD | PMID:22079256 | SGO2 | Human | progesterone | decreases expression | EXP | | 6480464 | Progesterone results in decreased expression of SGO2 mRNA | CTD | PMID:21795739 | SGO2 | Human | quercetin | decreases expression | EXP | | 6480464 | Quercetin results in decreased expression of SGO2 mRNA | CTD | PMID:21632981 | SGO2 | Human | resveratrol | multiple interactions | EXP | | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of SGO2 mRNA | CTD | PMID:19167446 | SGO2 | Human | resveratrol | increases expression | EXP | | 6480464 | resveratrol results in increased expression of SGO2 mRNA | CTD | PMID:19167446 | SGO2 | Human | rotenone | decreases expression | EXP | | 6480464 | Rotenone results in decreased expression of SGO2 mRNA | CTD | PMID:29955902 | SGO2 | Human | rotenone | increases expression | EXP | | 6480464 | Rotenone results in increased expression of SGO2 mRNA | CTD | PMID:33512557 | SGO2 | Human | rotenone | decreases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Rotenone results in decreased expression of SGO2 mRNA | CTD | PMID:28374803 | SGO2 | Human | silver atom | decreases expression | ISO | Sgo2a (Mus musculus) | 6480464 | Silver results in decreased expression of SGO2A mRNA | CTD | PMID:27131904 | SGO2 | Human | silver(0) | decreases expression | ISO | Sgo2a (Mus musculus) | 6480464 | Silver results in decreased expression of SGO2A mRNA | CTD | PMID:27131904 | SGO2 | Human | sodium arsenite | increases expression | EXP | | 6480464 | sodium arsenite results in increased expression of SGO2 mRNA | CTD | PMID:29301061 | SGO2 | Human | sodium arsenite | decreases expression | ISO | Sgo2a (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of SGO2A mRNA | CTD | PMID:36209798 | SGO2 | Human | sulforaphane | increases expression | EXP | | 6480464 | sulforaphane results in increased expression of SGO2 mRNA | CTD | PMID:31838189 | SGO2 | Human | sunitinib | decreases expression | EXP | | 6480464 | Sunitinib results in decreased expression of SGO2 mRNA | CTD | PMID:31533062 | SGO2 | Human | testosterone | decreases expression | EXP | | 6480464 | Testosterone results in decreased expression of SGO2 mRNA | CTD | PMID:21592394 | SGO2 | Human | testosterone | multiple interactions | ISO | Sgo2 (Rattus norvegicus) | 6480464 | [estradiol 3-benzoate co-treated with [Testosterone co-treated with Estradiol]] results in increased expression of SGO2 mRNA | CTD | PMID:32741896 | SGO2 | Human | testosterone | multiple interactions | EXP | | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of SGO2 mRNA | CTD | PMID:21592394 | SGO2 | Human | tetrachloromethane | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | Carbon Tetrachloride results in increased expression of SGO2A mRNA | CTD | PMID:31919559 | SGO2 | Human | thioacetamide | increases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Thioacetamide results in increased expression of SGO2 mRNA | CTD | PMID:34492290 | SGO2 | Human | trichloroethene | decreases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | Trichloroethylene results in decreased expression of SGO2 mRNA | CTD | PMID:33387578 | SGO2 | Human | trimellitic anhydride | increases expression | ISO | Sgo2a (Mus musculus) | 6480464 | trimellitic anhydride results in increased expression of SGO2 mRNA | CTD | PMID:19042947 | SGO2 | Human | triphenyl phosphate | affects expression | EXP | | 6480464 | triphenyl phosphate affects the expression of SGO2 mRNA | CTD | PMID:37042841 | SGO2 | Human | triticonazole | decreases expression | ISO | Sgo2 (Rattus norvegicus) | 6480464 | triticonazole results in decreased expression of SGO2 mRNA | CTD | PMID:36084822 | SGO2 | Human | troglitazone | decreases expression | EXP | | 6480464 | troglitazone results in decreased expression of SGO2 mRNA | CTD | PMID:19140230 | SGO2 | Human | trovafloxacin | decreases expression | ISO | Sgo2a (Mus musculus) | 6480464 | trovafloxacin results in decreased expression of SGO2A mRNA | CTD | PMID:35537566 | SGO2 | Human | valproic acid | decreases methylation | EXP | | 6480464 | Valproic Acid results in decreased methylation of SGO2 gene | CTD | PMID:29154799 | SGO2 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of SGO2 mRNA | CTD | PMID:25979313 | SGO2 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of SGO2 mRNA | CTD | PMID:23179753 and PMID:27188386 | SGO2 | Human | vorinostat | increases expression | EXP | | 6480464 | vorinostat results in increased expression of SGO2 mRNA | CTD | PMID:27188386 | |